永泰生物-B(06978.HK)躋身2021“科創中國”先導技術榜單

2022年2月9日,中國科學技術協會公示了2021“科創中國”榜單遴選結果。永泰生物憑藉“個體化細胞治療藥物——擴增活化的淋巴細胞(EAL®)關鍵技術應用”突圍入選2021“科創中國”先導技術榜(生物醫藥領域)榜單。
2021“科創中國”先導技術榜聚焦生物醫藥、電子信息、裝備製造、先進材料、資源環境、現代農林等六大領域,從技術成果的可行性、先進性、原創性、不可替代性、技術成熟度和市場前景等多維度進行初評與相關領域權威專家終評,旨在從全國範圍內遴選出能夠彰顯和代表本領域前沿水平,面向產業需求實現重大突破,商業模式清晰,商業潛力巨大,可轉化、可轉移、可交易,具有產業先導意義的技術成果。在生物醫藥領域,永泰生物、中國人民解放軍空軍軍醫大學、中國醫學科學院阜外醫院、北京大學口腔醫院等十八家單位成果入選。
關於EAL®
肝癌是惡性程度最高的腫瘤之一,肝癌術後復發是其主要致死因素。據統計,在中國肝癌患者術後腫瘤復發轉移率高達40%~70%,五年生存率僅為10~19%。EAL®是我國首個、也是目前為止唯一一項被國家藥監局批准、正在進行確證性II期臨牀試驗、適應症為預防肝癌術後復發的實體瘤免疫細胞藥物,將有望打破肝癌術後“無藥可醫”的困局,為延長肝癌患者的生存期帶來全新治療手段,填補國內實體瘤細胞免疫治療領域空白,釋放出巨大的社會經濟效益。
來源:永泰生物官微
原標題:永泰生物-B(06978.HK)躋身2021“科創中國”先導技術榜單
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.